Hypothesis: XX individuals maintain a more resilient gut microbiome with higher butyrate‑producing capacity than XY individuals because X‑linked immune and barrier genes escape dosage compensation, giving duplicated expression that shapes microbial ecology.

Mechanistic rationale: The X chromosome encodes dozens of genes involved in mucosal immunity, mucus secretion, and epithelial metabolism (e.g., TLR7, CX3CR1, MUC2 regulators). In females, these genes often escape X‑inactivation, yielding ~1.5‑fold higher expression relative to males [1][2]. Elevated expression enhances secretion of antimicrobial peptides and mucin layers that favor strict anaerobes such as Roseburia spp. and Faecalibacterium prausnitzii while suppressing mucin‑degrading opportunists like Akkermansia muciniphila. Escapee genes may also drive sex‑biased DNA methylation patterns at promoters of mucin‑glycosyltransferases, further biasing the mucosal glycome toward structures that promote butyrate‑producer adhesion. Consequently, XX colons generate more luminal butyrate, which fuels colonocyte oxidative metabolism, reinforces barrier integrity, and dampens systemic inflammation—a cascade linked to extended lifespan in long‑lived families [4][5][6].

Testable predictions:

1. In germ‑free mice colonized with a standardized microbiota, XX mice (ovariectomized to remove hormonal confounding) will show significantly greater fecal butyrate concentrations and higher relative abundance of butyrate‑producing taxa than XY mice, despite identical gonadal status.
2. Mice with atypical sex chromosome complements (XO, XXY) will display intermediate phenotypes correlating with X‑chromosome dose, independent of Sry‑driven testicular development.
3. Transplanting feces from young XX donors into aged XY recipients will restore butyrate levels and improve colonocyte histology more effectively than the reciprocal transfer.
4. CRISPR‑mediated knockout of an X‑linked escapee (e.g., Tlr7) in XX mice will reduce butyrate production to XY‑like levels, abolishing the longevity‑associated microbiome signature.
5. Administering a microbiome‑targeted prebiotic that selectively fuels butyrate producers will diminish the survival gap between XX and XY mice if the X‑chromosome effect is mediated through microbial metabolites.

Falsifiability: If metagenomic and metabolomic analyses reveal no consistent differences in butyrate‑producing bacteria or fecal butyrate between XX and XY mice after controlling for gonadal hormones, or if manipulating X‑gene dosage fails to shift microbiome composition, the hypothesis is refuted. Likewise, if the prebiotic intervention does not narrow the sex‑specific lifespan difference, the causal link to microbiota is weakened.

Broader implication: It's well established that aging reduces beneficial butyrate‑producers like Roseburia intestinalis, Roseburia obeum, and Faecalibacterium prausnitzii while increasing mucin‑degrading bacteria like Akkermansia muciniphila [4]. By linking X‑chromosome dosage to microbial resilience, we're offering a testable route to decouple hormonal influence from genetic dosage in longevity research. This framework redirects the search for longevity mechanisms from hormonal modulation to sex‑chromosome gene dosage, offering a genetically tractable avenue to harness the microbiome for healthspan extension. Furthermore, sex‑chromosome‑aware probiotic or gene‑therapy strategies could one day mitigate the male‑specific deficit in colonic butyrate, narrowing the longevity gap.